The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Mesalamine (Lialda) Market Research Report 2024
Synopsis
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease 2. It is considered to be the active moiety of sulphasalazine. (From Martindale, The Extra Pharmacopoeia, 30th ed) Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent.
The global Mesalamine (Lialda) market was valued at US$ 156.5 million in 2023 and is anticipated to reach US$ 228 million by 2030, witnessing a CAGR of 5.6% during the forecast period 2024-2030.
North American market for Mesalamine (Lialda) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Mesalamine (Lialda) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Mesalamine (Lialda) in Colitis is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Mesalamine (Lialda) include Dr.Falk Pharma, Ferring, Ethypharm Pharmaceutical, Shanghai Pharmaceutical, Tillotts Pharma, Holy Stone Healthcare, Giuliani, Zeria and Lupin, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Mesalamine (Lialda), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mesalamine (Lialda).
Report Scope
The Mesalamine (Lialda) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Mesalamine (Lialda) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Mesalamine (Lialda) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Dr.Falk Pharma
Ferring
Ethypharm Pharmaceutical
Shanghai Pharmaceutical
Tillotts Pharma
Holy Stone Healthcare
Giuliani
Zeria
Lupin
Heilongjiang Tianhong Pharmaceutical
HENGCHENG PHARMACEUTICAL
KWAI FA Pharmaceutical Group
Segment by Type
Enemas
Tablets
Suppositories
Other
Segment by Application
Colitis
Crohn's Disease
Proctitis
Diarrheal Irritable Bowel Syndrome
Diverticulitis
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Mesalamine (Lialda) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease 2. It is considered to be the active moiety of sulphasalazine. (From Martindale, The Extra Pharmacopoeia, 30th ed) Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent.
The global Mesalamine (Lialda) market was valued at US$ 156.5 million in 2023 and is anticipated to reach US$ 228 million by 2030, witnessing a CAGR of 5.6% during the forecast period 2024-2030.
North American market for Mesalamine (Lialda) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Mesalamine (Lialda) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Mesalamine (Lialda) in Colitis is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Mesalamine (Lialda) include Dr.Falk Pharma, Ferring, Ethypharm Pharmaceutical, Shanghai Pharmaceutical, Tillotts Pharma, Holy Stone Healthcare, Giuliani, Zeria and Lupin, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Mesalamine (Lialda), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mesalamine (Lialda).
Report Scope
The Mesalamine (Lialda) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Mesalamine (Lialda) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Mesalamine (Lialda) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Dr.Falk Pharma
Ferring
Ethypharm Pharmaceutical
Shanghai Pharmaceutical
Tillotts Pharma
Holy Stone Healthcare
Giuliani
Zeria
Lupin
Heilongjiang Tianhong Pharmaceutical
HENGCHENG PHARMACEUTICAL
KWAI FA Pharmaceutical Group
Segment by Type
Enemas
Tablets
Suppositories
Other
Segment by Application
Colitis
Crohn's Disease
Proctitis
Diarrheal Irritable Bowel Syndrome
Diverticulitis
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Mesalamine (Lialda) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Mesalamine (Lialda) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Enemas
1.2.3 Tablets
1.2.4 Suppositories
1.2.5 Other
1.3 Market by Application
1.3.1 Global Mesalamine (Lialda) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Colitis
1.3.3 Crohn's Disease
1.3.4 Proctitis
1.3.5 Diarrheal Irritable Bowel Syndrome
1.3.6 Diverticulitis
1.3.7 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Mesalamine (Lialda) Market Perspective (2019-2030)
2.2 Mesalamine (Lialda) Growth Trends by Region
2.2.1 Global Mesalamine (Lialda) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Mesalamine (Lialda) Historic Market Size by Region (2019-2024)
2.2.3 Mesalamine (Lialda) Forecasted Market Size by Region (2025-2030)
2.3 Mesalamine (Lialda) Market Dynamics
2.3.1 Mesalamine (Lialda) Industry Trends
2.3.2 Mesalamine (Lialda) Market Drivers
2.3.3 Mesalamine (Lialda) Market Challenges
2.3.4 Mesalamine (Lialda) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Mesalamine (Lialda) Players by Revenue
3.1.1 Global Top Mesalamine (Lialda) Players by Revenue (2019-2024)
3.1.2 Global Mesalamine (Lialda) Revenue Market Share by Players (2019-2024)
3.2 Global Mesalamine (Lialda) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Mesalamine (Lialda) Revenue
3.4 Global Mesalamine (Lialda) Market Concentration Ratio
3.4.1 Global Mesalamine (Lialda) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Mesalamine (Lialda) Revenue in 2023
3.5 Mesalamine (Lialda) Key Players Head office and Area Served
3.6 Key Players Mesalamine (Lialda) Product Solution and Service
3.7 Date of Enter into Mesalamine (Lialda) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Mesalamine (Lialda) Breakdown Data by Type
4.1 Global Mesalamine (Lialda) Historic Market Size by Type (2019-2024)
4.2 Global Mesalamine (Lialda) Forecasted Market Size by Type (2025-2030)
5 Mesalamine (Lialda) Breakdown Data by Application
5.1 Global Mesalamine (Lialda) Historic Market Size by Application (2019-2024)
5.2 Global Mesalamine (Lialda) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Mesalamine (Lialda) Market Size (2019-2030)
6.2 North America Mesalamine (Lialda) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Mesalamine (Lialda) Market Size by Country (2019-2024)
6.4 North America Mesalamine (Lialda) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Mesalamine (Lialda) Market Size (2019-2030)
7.2 Europe Mesalamine (Lialda) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Mesalamine (Lialda) Market Size by Country (2019-2024)
7.4 Europe Mesalamine (Lialda) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Mesalamine (Lialda) Market Size (2019-2030)
8.2 Asia-Pacific Mesalamine (Lialda) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Mesalamine (Lialda) Market Size by Region (2019-2024)
8.4 Asia-Pacific Mesalamine (Lialda) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Mesalamine (Lialda) Market Size (2019-2030)
9.2 Latin America Mesalamine (Lialda) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Mesalamine (Lialda) Market Size by Country (2019-2024)
9.4 Latin America Mesalamine (Lialda) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Mesalamine (Lialda) Market Size (2019-2030)
10.2 Middle East & Africa Mesalamine (Lialda) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Mesalamine (Lialda) Market Size by Country (2019-2024)
10.4 Middle East & Africa Mesalamine (Lialda) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Dr.Falk Pharma
11.1.1 Dr.Falk Pharma Company Detail
11.1.2 Dr.Falk Pharma Business Overview
11.1.3 Dr.Falk Pharma Mesalamine (Lialda) Introduction
11.1.4 Dr.Falk Pharma Revenue in Mesalamine (Lialda) Business (2019-2024)
11.1.5 Dr.Falk Pharma Recent Development
11.2 Ferring
11.2.1 Ferring Company Detail
11.2.2 Ferring Business Overview
11.2.3 Ferring Mesalamine (Lialda) Introduction
11.2.4 Ferring Revenue in Mesalamine (Lialda) Business (2019-2024)
11.2.5 Ferring Recent Development
11.3 Ethypharm Pharmaceutical
11.3.1 Ethypharm Pharmaceutical Company Detail
11.3.2 Ethypharm Pharmaceutical Business Overview
11.3.3 Ethypharm Pharmaceutical Mesalamine (Lialda) Introduction
11.3.4 Ethypharm Pharmaceutical Revenue in Mesalamine (Lialda) Business (2019-2024)
11.3.5 Ethypharm Pharmaceutical Recent Development
11.4 Shanghai Pharmaceutical
11.4.1 Shanghai Pharmaceutical Company Detail
11.4.2 Shanghai Pharmaceutical Business Overview
11.4.3 Shanghai Pharmaceutical Mesalamine (Lialda) Introduction
11.4.4 Shanghai Pharmaceutical Revenue in Mesalamine (Lialda) Business (2019-2024)
11.4.5 Shanghai Pharmaceutical Recent Development
11.5 Tillotts Pharma
11.5.1 Tillotts Pharma Company Detail
11.5.2 Tillotts Pharma Business Overview
11.5.3 Tillotts Pharma Mesalamine (Lialda) Introduction
11.5.4 Tillotts Pharma Revenue in Mesalamine (Lialda) Business (2019-2024)
11.5.5 Tillotts Pharma Recent Development
11.6 Holy Stone Healthcare
11.6.1 Holy Stone Healthcare Company Detail
11.6.2 Holy Stone Healthcare Business Overview
11.6.3 Holy Stone Healthcare Mesalamine (Lialda) Introduction
11.6.4 Holy Stone Healthcare Revenue in Mesalamine (Lialda) Business (2019-2024)
11.6.5 Holy Stone Healthcare Recent Development
11.7 Giuliani
11.7.1 Giuliani Company Detail
11.7.2 Giuliani Business Overview
11.7.3 Giuliani Mesalamine (Lialda) Introduction
11.7.4 Giuliani Revenue in Mesalamine (Lialda) Business (2019-2024)
11.7.5 Giuliani Recent Development
11.8 Zeria
11.8.1 Zeria Company Detail
11.8.2 Zeria Business Overview
11.8.3 Zeria Mesalamine (Lialda) Introduction
11.8.4 Zeria Revenue in Mesalamine (Lialda) Business (2019-2024)
11.8.5 Zeria Recent Development
11.9 Lupin
11.9.1 Lupin Company Detail
11.9.2 Lupin Business Overview
11.9.3 Lupin Mesalamine (Lialda) Introduction
11.9.4 Lupin Revenue in Mesalamine (Lialda) Business (2019-2024)
11.9.5 Lupin Recent Development
11.10 Heilongjiang Tianhong Pharmaceutical
11.10.1 Heilongjiang Tianhong Pharmaceutical Company Detail
11.10.2 Heilongjiang Tianhong Pharmaceutical Business Overview
11.10.3 Heilongjiang Tianhong Pharmaceutical Mesalamine (Lialda) Introduction
11.10.4 Heilongjiang Tianhong Pharmaceutical Revenue in Mesalamine (Lialda) Business (2019-2024)
11.10.5 Heilongjiang Tianhong Pharmaceutical Recent Development
11.11 HENGCHENG PHARMACEUTICAL
11.11.1 HENGCHENG PHARMACEUTICAL Company Detail
11.11.2 HENGCHENG PHARMACEUTICAL Business Overview
11.11.3 HENGCHENG PHARMACEUTICAL Mesalamine (Lialda) Introduction
11.11.4 HENGCHENG PHARMACEUTICAL Revenue in Mesalamine (Lialda) Business (2019-2024)
11.11.5 HENGCHENG PHARMACEUTICAL Recent Development
11.12 KWAI FA Pharmaceutical Group
11.12.1 KWAI FA Pharmaceutical Group Company Detail
11.12.2 KWAI FA Pharmaceutical Group Business Overview
11.12.3 KWAI FA Pharmaceutical Group Mesalamine (Lialda) Introduction
11.12.4 KWAI FA Pharmaceutical Group Revenue in Mesalamine (Lialda) Business (2019-2024)
11.12.5 KWAI FA Pharmaceutical Group Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Mesalamine (Lialda) Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Enemas
Table 3. Key Players of Tablets
Table 4. Key Players of Suppositories
Table 5. Key Players of Other
Table 6. Global Mesalamine (Lialda) Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Mesalamine (Lialda) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Mesalamine (Lialda) Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Mesalamine (Lialda) Market Share by Region (2019-2024)
Table 10. Global Mesalamine (Lialda) Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Mesalamine (Lialda) Market Share by Region (2025-2030)
Table 12. Mesalamine (Lialda) Market Trends
Table 13. Mesalamine (Lialda) Market Drivers
Table 14. Mesalamine (Lialda) Market Challenges
Table 15. Mesalamine (Lialda) Market Restraints
Table 16. Global Mesalamine (Lialda) Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Mesalamine (Lialda) Market Share by Players (2019-2024)
Table 18. Global Top Mesalamine (Lialda) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mesalamine (Lialda) as of 2023)
Table 19. Ranking of Global Top Mesalamine (Lialda) Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Mesalamine (Lialda) Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Mesalamine (Lialda) Product Solution and Service
Table 23. Date of Enter into Mesalamine (Lialda) Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Mesalamine (Lialda) Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Mesalamine (Lialda) Revenue Market Share by Type (2019-2024)
Table 27. Global Mesalamine (Lialda) Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Mesalamine (Lialda) Revenue Market Share by Type (2025-2030)
Table 29. Global Mesalamine (Lialda) Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Mesalamine (Lialda) Revenue Market Share by Application (2019-2024)
Table 31. Global Mesalamine (Lialda) Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Mesalamine (Lialda) Revenue Market Share by Application (2025-2030)
Table 33. North America Mesalamine (Lialda) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Mesalamine (Lialda) Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Mesalamine (Lialda) Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Mesalamine (Lialda) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Mesalamine (Lialda) Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Mesalamine (Lialda) Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Mesalamine (Lialda) Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Mesalamine (Lialda) Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Mesalamine (Lialda) Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Mesalamine (Lialda) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Mesalamine (Lialda) Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Mesalamine (Lialda) Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Mesalamine (Lialda) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Mesalamine (Lialda) Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Mesalamine (Lialda) Market Size by Country (2025-2030) & (US$ Million)
Table 48. Dr.Falk Pharma Company Detail
Table 49. Dr.Falk Pharma Business Overview
Table 50. Dr.Falk Pharma Mesalamine (Lialda) Product
Table 51. Dr.Falk Pharma Revenue in Mesalamine (Lialda) Business (2019-2024) & (US$ Million)
Table 52. Dr.Falk Pharma Recent Development
Table 53. Ferring Company Detail
Table 54. Ferring Business Overview
Table 55. Ferring Mesalamine (Lialda) Product
Table 56. Ferring Revenue in Mesalamine (Lialda) Business (2019-2024) & (US$ Million)
Table 57. Ferring Recent Development
Table 58. Ethypharm Pharmaceutical Company Detail
Table 59. Ethypharm Pharmaceutical Business Overview
Table 60. Ethypharm Pharmaceutical Mesalamine (Lialda) Product
Table 61. Ethypharm Pharmaceutical Revenue in Mesalamine (Lialda) Business (2019-2024) & (US$ Million)
Table 62. Ethypharm Pharmaceutical Recent Development
Table 63. Shanghai Pharmaceutical Company Detail
Table 64. Shanghai Pharmaceutical Business Overview
Table 65. Shanghai Pharmaceutical Mesalamine (Lialda) Product
Table 66. Shanghai Pharmaceutical Revenue in Mesalamine (Lialda) Business (2019-2024) & (US$ Million)
Table 67. Shanghai Pharmaceutical Recent Development
Table 68. Tillotts Pharma Company Detail
Table 69. Tillotts Pharma Business Overview
Table 70. Tillotts Pharma Mesalamine (Lialda) Product
Table 71. Tillotts Pharma Revenue in Mesalamine (Lialda) Business (2019-2024) & (US$ Million)
Table 72. Tillotts Pharma Recent Development
Table 73. Holy Stone Healthcare Company Detail
Table 74. Holy Stone Healthcare Business Overview
Table 75. Holy Stone Healthcare Mesalamine (Lialda) Product
Table 76. Holy Stone Healthcare Revenue in Mesalamine (Lialda) Business (2019-2024) & (US$ Million)
Table 77. Holy Stone Healthcare Recent Development
Table 78. Giuliani Company Detail
Table 79. Giuliani Business Overview
Table 80. Giuliani Mesalamine (Lialda) Product
Table 81. Giuliani Revenue in Mesalamine (Lialda) Business (2019-2024) & (US$ Million)
Table 82. Giuliani Recent Development
Table 83. Zeria Company Detail
Table 84. Zeria Business Overview
Table 85. Zeria Mesalamine (Lialda) Product
Table 86. Zeria Revenue in Mesalamine (Lialda) Business (2019-2024) & (US$ Million)
Table 87. Zeria Recent Development
Table 88. Lupin Company Detail
Table 89. Lupin Business Overview
Table 90. Lupin Mesalamine (Lialda) Product
Table 91. Lupin Revenue in Mesalamine (Lialda) Business (2019-2024) & (US$ Million)
Table 92. Lupin Recent Development
Table 93. Heilongjiang Tianhong Pharmaceutical Company Detail
Table 94. Heilongjiang Tianhong Pharmaceutical Business Overview
Table 95. Heilongjiang Tianhong Pharmaceutical Mesalamine (Lialda) Product
Table 96. Heilongjiang Tianhong Pharmaceutical Revenue in Mesalamine (Lialda) Business (2019-2024) & (US$ Million)
Table 97. Heilongjiang Tianhong Pharmaceutical Recent Development
Table 98. HENGCHENG PHARMACEUTICAL Company Detail
Table 99. HENGCHENG PHARMACEUTICAL Business Overview
Table 100. HENGCHENG PHARMACEUTICAL Mesalamine (Lialda) Product
Table 101. HENGCHENG PHARMACEUTICAL Revenue in Mesalamine (Lialda) Business (2019-2024) & (US$ Million)
Table 102. HENGCHENG PHARMACEUTICAL Recent Development
Table 103. KWAI FA Pharmaceutical Group Company Detail
Table 104. KWAI FA Pharmaceutical Group Business Overview
Table 105. KWAI FA Pharmaceutical Group Mesalamine (Lialda) Product
Table 106. KWAI FA Pharmaceutical Group Revenue in Mesalamine (Lialda) Business (2019-2024) & (US$ Million)
Table 107. KWAI FA Pharmaceutical Group Recent Development
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Mesalamine (Lialda) Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Mesalamine (Lialda) Market Share by Type: 2023 VS 2030
Figure 3. Enemas Features
Figure 4. Tablets Features
Figure 5. Suppositories Features
Figure 6. Other Features
Figure 7. Global Mesalamine (Lialda) Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Mesalamine (Lialda) Market Share by Application: 2023 VS 2030
Figure 9. Colitis Case Studies
Figure 10. Crohn's Disease Case Studies
Figure 11. Proctitis Case Studies
Figure 12. Diarrheal Irritable Bowel Syndrome Case Studies
Figure 13. Diverticulitis Case Studies
Figure 14. Other Case Studies
Figure 15. Mesalamine (Lialda) Report Years Considered
Figure 16. Global Mesalamine (Lialda) Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 17. Global Mesalamine (Lialda) Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 18. Global Mesalamine (Lialda) Market Share by Region: 2023 VS 2030
Figure 19. Global Mesalamine (Lialda) Market Share by Players in 2023
Figure 20. Global Top Mesalamine (Lialda) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mesalamine (Lialda) as of 2023)
Figure 21. The Top 10 and 5 Players Market Share by Mesalamine (Lialda) Revenue in 2023
Figure 22. North America Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. North America Mesalamine (Lialda) Market Share by Country (2019-2030)
Figure 24. United States Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Canada Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Mesalamine (Lialda) Market Share by Country (2019-2030)
Figure 28. Germany Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. France Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. U.K. Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Italy Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Russia Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Nordic Countries Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Mesalamine (Lialda) Market Share by Region (2019-2030)
Figure 36. China Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Japan Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. South Korea Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. India Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Australia Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Mesalamine (Lialda) Market Share by Country (2019-2030)
Figure 44. Mexico Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Brazil Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Mesalamine (Lialda) Market Share by Country (2019-2030)
Figure 48. Turkey Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Mesalamine (Lialda) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Dr.Falk Pharma Revenue Growth Rate in Mesalamine (Lialda) Business (2019-2024)
Figure 51. Ferring Revenue Growth Rate in Mesalamine (Lialda) Business (2019-2024)
Figure 52. Ethypharm Pharmaceutical Revenue Growth Rate in Mesalamine (Lialda) Business (2019-2024)
Figure 53. Shanghai Pharmaceutical Revenue Growth Rate in Mesalamine (Lialda) Business (2019-2024)
Figure 54. Tillotts Pharma Revenue Growth Rate in Mesalamine (Lialda) Business (2019-2024)
Figure 55. Holy Stone Healthcare Revenue Growth Rate in Mesalamine (Lialda) Business (2019-2024)
Figure 56. Giuliani Revenue Growth Rate in Mesalamine (Lialda) Business (2019-2024)
Figure 57. Zeria Revenue Growth Rate in Mesalamine (Lialda) Business (2019-2024)
Figure 58. Lupin Revenue Growth Rate in Mesalamine (Lialda) Business (2019-2024)
Figure 59. Heilongjiang Tianhong Pharmaceutical Revenue Growth Rate in Mesalamine (Lialda) Business (2019-2024)
Figure 60. HENGCHENG PHARMACEUTICAL Revenue Growth Rate in Mesalamine (Lialda) Business (2019-2024)
Figure 61. KWAI FA Pharmaceutical Group Revenue Growth Rate in Mesalamine (Lialda) Business (2019-2024)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
